CsA inhibits IL-22 production by memory CD4+ T cells from patients with psoriasis by Shen Erxia et al.
Arch. Biol. Sci., Belgrade, 66 (2), 775-784, 2014 DOI:10.2298/ABS1402775S
775
CsA INHIBITs IL-22 PRODUCTION BY MEMORY CD4+ T CELLs FROM PATIENTs  
WITH PsORIAsIs
ERXIA SHEN
1, BAOXIN Y ANG
1, Y ANG LI
1, Q IWEN LIN
2, RUQIONG ZOU
1, HUAYI HUANG
1, JIE 
WU
1, SHUXIA ZHANG
1, JUNTAO ZOU
3, MAOHUA ZHOU
4* and Y APING TANG
5*
1 Department of Pathogenic Bio logy and Immunology, School of Basic Medicine, Guangzhou Medical University, 
Guangzhou 510182, China 
2 Guangzhou Blood Center, Guangzhou 510095, China 
3 Department of Anatomy and Neurobiology, Zhongshan School of Medicine, Sun Yat-sen University,  
Guangzhou 510080, China 
4 Department of Laboratory Medicine, Guangdong General Hospital; Academy of Medical Sciences, Guangzhou 510080, 
China 
5 Guangzhou Institute of Dermatology , Guangzhou 510095, China
Abstract - IL-22 is involved in psoriasis and exacerbates disease progression. Cyclosporine A (CsA) is an immunosup-
pressant drug that has been used in the treatment of psoriasis for more than 20 years. We determined IL-22 producing T 
cells and their phenotype, and demonstrated that IL-22 is mainly produced by CD4+ memory T cells not CD8+ T cells in 
peripheral blood from healthy adults. We compared Th17 and Th1 with the percentages of IL-22 producing CD4+ T cells, 
and demonstrated that Th1 is the majority Th subset in the blood, as the percentage of Th1 cells is significantly larger than 
the percentage of IL-22 producing CD4+ T cells or Th17 cells. We analyzed the correlation of IL-22, IL-17 and IFN-γ pro-
duced by CD4+ T cells from healthy adults, and confirmed that there is a subset of Th22 cells that does not produce IL-17 
or IFN-γ. Furthermore, we observed that the percentage of IL-22 producing CD4+ T cells is elevated in psoriasis compared 
to healthy donors, and that the majority of these cells are memory CD4+ T cells. We also investigated the inhibitory effects 
of CsA on IL-22 production by CD4+ T cells from both healthy donors and patients with psoriasis. We observed that CsA 
inhibits the production of IL-22 by CD4+ T cells from healthy donors in a dose-dependent manner, and that it inhibits IL-
22, IFN-γ and IL-17 production by CD4+ T cells in psoriasis. The obtained results provide critical information regarding 
the clinical efficacies of CsA in the treatment of psoriasis.
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INTRODUCTION
Psoriasis is one of the most common chronic in-
flammatory skin diseases. It affects about 2% of the 
world’s  population,  and  85%-90%  of  all  patients 
with this disease present psoriasis vulgaris (Nestle et 
al., 2009; Lowes et al., 2007). This disease is usually 
characterized by a thickened epidermis, hyperpro-
liferation and abnormal differentiation of keratinoc-
ytes, vascular hyperplasia and infiltration of inflam-
matory immune cells. T cells play a key role in the 
pathogenesis of psoriasis.776 ERXIA SHEN ET AL.
According to their functions, the secreted cy-
tokines and transcriptional factors, CD4+ T helper 
cells are divided into several subsets, such as Th1, 
Th2 and Th17, and so on. Th1 cells produce cy-
tokine IFN-γ, Th2 produce IL-4, and Th17 cells se-
crete IL-17 (Chen and O’Shea, 2008; Sallusto et al., 
2012). It is thought that Th1 and Th17 cells play a 
predominant role in the pathogenesis of psoriasis 
(Austin et al., 1999; Chiricozzi et al., 2012). Recent-
ly, a new Th subset, named Th22, which produces 
IL-22  but  does  not  express  IL-17  or  IFN-γ,  was 
identified (Duhen et al., 2009; Trifari et al., 2009). 
This subset is involved in epidermal immunity and 
remodeling (Eyerich et al., 2009; Fujita et al., 2009). 
It has been reported that Th22 cells are increased 
in blood in psoriasis, as are IL-22 plasma levels and 
that this correlates with disease severity. IL-22, as 
one of the key, mediators, is involved in psoriasis 
and exacerbates disease progression (Kagami et al., 
2010; Ouyang, 2010).
Cyclosporine A (CsA) is an immunosuppressant 
drug used in the treatment of psoriasis, transplanta-
tion, rheumatoid arthritis and other immune-medi-
ated diseases. CsA has been used to treat psoriasis in 
clinics for more than 20 years; it effectively controls 
psoriasis,  prolonging  the  relapse  time  in  psoriasis 
patients (Zachariae and Steen Olsen, 1995; Maza et 
al., 2011; Colombo et al., 2010). It has been demon-
strated that CsA inhibits IL-17 and IFN-γ produc-
tion by CD4+ T cells from healthy donors, in Beh-
cet’s and other diseases (Zhang et al., 2008; Chi et al., 
2010; Liu et al., 2009). IL-22 and IL-22 producing 
CD4+T cells are elevated in psoriasis and involved 
in the pathogenesis of psoriasis. In this article, we 
examined whether CsA inhibits IL-22 production by 
CD4+ T cells from healthy donors and patients with 
psoriasis.
MATERIALS AND METHODS
This study was approved by the Ethics Committee 
of  School  of  Basic  Medicine,  Guangzhou  Medical 
University (Guangzhou, China) and Guangzhou In-
stitute of Dermatology (Guangzhou, China). Written 
informed consent was obtained from all patients and 
healthy donors participating in this study.
Subjects
Healthy volunteers and psoriasis patients that donat-
ed blood samples for the study were recruited from 
Guangzhou Medical University and Guangzhou In-
stitute  of  Dermatology,  China.  Twenty-six  healthy 
donors and five psoriasis patients were recruited. The 
mean age of the healthy volunteers (14 male and 12 
female) was 26.7 years (ranging from 19-47 years). 
The mean age of adult psoriasis patients (1 male and 
4 female) was 39.8 years (ranging from 21-64 years). 
Exclusion criteria were local treatment with corti-
costeroids, phototherapy, or systemic corticosteroid 
therapy within 4 weeks of sample collection, patients 
with HIV, HBV, HCV or other autoimmune diseas-
es.
Reagents
Purified anti-CD3 mAb, purified anti-CD28 mAb, an-
ti-CD4 PerCP-cy5.5, anti-CD3 FITC, anti-CD45RO 
FITC, anti-IFN-γ FITC, anti-IFN-γ APC and iso-
type- matched control mAbs were purchased from 
BD PharMingen (San Diego, CA, USA). Anti-IL-17 
APC was purchased from eBioscience (San Diego, 
CA, USA). Anti-IL-22 PE was purchased from R&D 
Systems (Abingdon, UK). PMA, ionomycin, saponin 
and Brefeldin A were purchased from Sigma-Aldrich 
(Fluka, Sigma, USA). Cyclosporine A (CsA) was ob-
tained from Novartis (Novartis, Switzerland).
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were 
isolated from heparinized blood of healthy donors 
and  patients  with  psoriasis,  using  Ficoll-Hypaque 
density gradient centrifugation; the cells were washed 
twice in Hank’s balanced salt solution. The cells were 
adjusted  to  a  final  concentration  of  2×106/ml  in 
complete RPMI 1640 medium, supplemented with 
10% FCS (Sijiqing, China), 100 U/mL penicillin, 100 
mg/mL  streptomycin,  50  mM  2-mercaptoethanol, 
and 2 mM L-glutamine (all from GIBCO, Grand Is-
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Intracellular staining and flow cytometric analysis
PBMCs  were  stimulated  with  PMA  (20  ng/ml)  + 
ionomycin (1 µg/ml) in the presence or absence of 
CsA at different concentrations (0.01 µg/ml, 0.1µg/
ml, 1µg/ml) for 4-6 h at 37°C in a 5% CO2 humidi-
fied atmosphere. Brefeldin A (BFA, 10 μg/ml) was 
added to the culture at the end of first hour of in-
cubation. The cells were collected, washed twice in 
cold PBS, fixed with 4% paraformaldehyde and re-
suspended in permeabilization buffer (PBS contain-
ing 0.1% saponin and 0.5% BSA). After incubation 
at 4°C for 2 h or overnight, the cells were stained for 
the  presence  of  intracellular  cytokines  (anti-CD4 
PerCP-cy5.5, anti-CD3 FITC, anti-CD45RO FITC, 
anti-IL-17  APC,  anti-IL-22  PE,  anti-IFN-γ  FITC, 
and isotype-matched control mAbs) at 4°C for 25-30 
min. The cells were washed with PBS, resuspended 
in cold staining buffer and analyzed by FACSCalibur 
(BD Biosciences, San Jose, CA).
Statistics
The data are presented as the mean ± SD. Compari-
sons  between  two  groups  were  performed  by  un-
paired Student’s t-test; P < 0.05 was considered sta-
tistically significant.
RESULTS
IL-22 producing memory CD4+ T cells from health 
donors
First, we determined IL-22 producing CD4+ and CD8+ 
T cells of PBMCs from healthy donors stimulated 
with PMA plus ionomycin using FACS. Two subsets 
of CD3+ and CD4+ T cells: CD4+ T cells and CD3+ 
CD4- T cells (CD8+ T cells) were gated, and analyzed 
for IL-22 or IL-17 production. As shown in Fig. 1A, 
the percentage of IL-22 producing CD4+ T cells and 
CD8+ T cells was 1.96% and 0.08%, respectively, of 
IL-17 producing CD4+ T cells (Th17 and Th17/Th1) 
and CD8+ T cells (Tc17) was 1.48% and 0.24%, re-
spectively. We then compared the percentages of the 
IL-22 and IL-17 producing CD4+ T and CD8+ T cells. 
As shown in Fig.1B, IL-22 was mainly produced by 
CD4+ T cells (1.66±0.75%); very IL-22 was produced 
by a subset of CD8+ T cells (0.12±0.07%) (P<0.001). 
Similarly, IL-17 was produced mainly by CD4+ T cells 
(1.61±0.7%), and by a tiny subpopulation of CD8+ T 
cells (0.16±0.1%) (P<0.001).
We then determined the phenotypes of the IL-
22  producing  and  IL-17  producing  CD4+  T  cells. 
As shown in Fig 2, the majority of IL-22 producing 
(1.75% of CD4+ T cells) and IL-17 producing cells 
(1.3% of CD4+ T cells) expressed CD45RO on their 
surface.  Only  small  numbers  of  IL-22  producing 
(0.03% of CD4+ T cells) and IL-17 producing cells 
(0.03% of CD4+ T cells) did not express CD45RO. 
This means that IL-22 producing CD4+ T cells and 
Th17 cells are memory T cells.
The correlation of Th22, Th17 and Th1 from healthy 
donors
Th17 and Th1 cells can also produce the cytokine IL-
22. We determined that cytokines IL-22, IL-17 and 
IFN-γ were produced by CD4+ T cells from healthy 
donors. Analysis of their relationship showed that 
there  are  these  three  cell  subsets  in  PBMCs:  IL-
22 producing CD4+ T cells, Th17 cells (IL-17+ and 
IFN-γ-) and Th1 cells (IFN-γ+ IL-17-);  there is also a 
small population of CD4+ T cells that produced both 
IL-17 and IFN-γ , referred to as Th1/Th17 cells. The 
percentages of IL-22 producing CD4+ T cells, Th17 
cells and Th1 cells in CD4+ T cells are shown in Fig. 
3B. The percentage of Th1 in CD4+ T cells is greater 
than the percentages of the IL-22 producing CD4+ T 
cells and Th17 cells in PBMCs from health donors 
(P<0.001). There is no significant difference between 
the percentages of IL-22 producing CD4+ T cells and 
Th17 cells (P>0.05).
We then analyzed the relationship between IL-
22, IL-17 and IFN-γ. As shown in Fig. 4, some CD4+ 
T  cells  produced  both  IL-22  and  IL-17  (0.4%)  or 
both IL-22 and IFN-γ (1.06%); the mean values were 
0.38% and 0.73%, respectively. According to IL-17 
and/or IFN-γ production, the IL-22 producing CD4+ 
T cells were divided into four populations: IL-17+ 
IFN-γ-; IL-17+ IFN-γ+; IL-17- IFN-γ+; IL-17- IFN-γ- 778 ERXIA SHEN ET AL.
cells (this subset belongs to Th22 cells), with the mean 
percentages of the presence of these cell populations, 
15.75%,  8.61%,  33.60%  and  42.04%,  respectively. 
From these results, we concluded that there are some 
CD4+ T cells that produce two or three cytokines IL-
22, IL-17 and IFN-γ at the same time.
CsA inhibits IL-22 production by CD4+ T cells from 
healthy donors
Previous research has shown that CsA inhibits the 
immune response via inhibition of IL-17 and IFN-γ 
production by CD4+ T cells. We wanted to examine 
whether CsA inhibits IL-22 production by CD4+ T 
cells. PBMCs were stimulated with PMA and iono-
mycin in the presence or absence of different con-
centration of CsA, and the production of IL-22 and 
IFN-γ by CD4+ T cells was determined. From Fig.5 
we can see that CsA inhibited IL-22 and IFN-γ pro-
duction by CD4+ T cells from healthy donors in a 
dose-dependent manner. When the concentration of 
CsA was 0.01 µg/ml, the inhibitory ratio of IL-22 pro-
duction was 48.2±6.1%; at 0.1 and 1 µg /ml of CsA, 
the inhibitory ratio was 81.1±11.5% and 87.7±8.9%, 
respectively. Since there was no significant difference 
in the inhibitory ratios of IL-22 between 0.1 and 1 µg/
Fig. 1. IL-22 is mainly produced by CD4+ T cells and not by CD8+ T cells of healthy donors. PBMCs from healthy donors were stimu-
lated with PMA + ionomycin for 4-6 h. The cells were harvested, fixed, permeabilized, and cell surface and intracellular cytokine stain-
ing was assessed by FACS. A – IL-22 and IL-17 production by CD4+ T and CD8+ T cells from one donor (dot plots). B – data from eight 
separate experiments, as described in A. Each symbol represents one value from a single donor; the horizontal bars represent the mean 
values of all samples.CsA INHIBITS IL-22 PRODUCTION BY MEMORY CD4+ T CELLS FROM PATIENTS WITH PSORIASIS 779
Fig. 2. IL-22 produced by memory CD4+ T cells. PBMCs were stimulated with PMA + ionomycin for 4-6h. Cells were harvested and 
fixed, permeabilized, and subjected to cell surface staining for CD4 and CD45RO, and intracellular cytokine staining for IL-22, and ex-
amined by FACS. Isotype refers to control isotype staining. The numbers in the corner represent the percentage of cells in each quadrant. 
Data represent the result from one of eight similar results.
Fig. 3. Comparison of the percentages of IL-22+ CD4+ T cells, Th17 and Th1 cells in CD4+ T cells of healthy donors. A – IL-22, IL-17 or 
IFN-γ production by CD4+ T cells of PBMCs from one donor (dot plots). B – data of IL-22+ CD4+ T cells, Th17, or Th1, as described in 
A, are shown. Each symbol represents one value from a single donor and horizontal bars represent the mean value of all samples; **, P 
< 0.001; n.s, P> 0.05.780 ERXIA SHEN ET AL.
ml of CsA, we used 0.1 µg/ml of CsA in the following 
experiments. Similar results were also obtained for 
the inhibitory effect of CsA on IFN-γ production.
CsA inhibits IL-22 production by memory CD4+ T 
cells in psoriasis
 The percentage of IL-22+ CD4+ T cells in CD4+ T 
cells from 5 different individuals with psoriasis were 
determined. The percentage of IL-22+ CD4+ T cells 
ranged  from  1.09-5.31%.  The  majority  of  IL-22+ 
CD4+ T cells in psoriasis are CD45RO+ memory T 
cells (Fig. 6A). Compared with the percentages of 
IL-22+ CD4+ T cells from healthy donors, the IL-22+ 
CD4+  T  cells  were  elevated  in  psoriasis  (Fig.  6B). 
Next, we determined whether CsA could inhibit IL-
22 production by CD4+ T cells in psoriasis. As shown 
in Fig. 6, CsA inhibited IL-22 production by CD4+ T 
cells in psoriasis, and also inhibited IL-17 and IFN-γ 
production by CD4+ T cells.
DISCUSSION
IL-22 is a member of the IL-10 family of cytokines 
that includes IL-19, IL-20, IL-22, IL-24 and IL-26. It 
signals through the IL-22 receptor (IL-22R1 and IL-
10R1) whose expression is restricted to tissue epithe-
lia such as skin and intestine but not immune cells 
(Ouyang, 2010; Rutz et al., 2013). IL-22 is mainly 
produced by CD4+ T cells, lymphoid tissue inducer 
cells (LTi cells), and by NKT and γδT cells involved 
in regulation of immunity, inflammation and tissue 
homeostasis at barrier surfaces (Zenevicz and Fla-
vell, 2011; Sonnenberg et al., 2011).
Fig. 4. Correlation of IL-22, IL-17 and IFN-γ produced by CD4+ T cells of healthy donors. A – the relationships between IL-22 and IL-
17, IL-22 and IFN-γ and IL-17 and IFN-γ produced by CD4+ T cells in PBMCs of from one representative healthy donor. B – the mean 
value of A are shown from nine separate experiments.CsA INHIBITS IL-22 PRODUCTION BY MEMORY CD4+ T CELLS FROM PATIENTS WITH PSORIASIS 781
In psoriasis IL-22, as one of the key mediators, in-
duces many of the pathogenic phenotypes and exac-
erbates disease progression. It has been reported that 
IL-22 plasma levels are strongly elevated in psoriasis, 
and  that  they  correlate  with  disease  severity  (Mu-
rakami et al., 2011). Moreover, enhanced expression 
of IL-22 mRNA and protein has been found in skin 
lesions from psoriasis patients, and was involved in 
imiquimod-induced psoriasiform skin inflammation 
in mice (Van Belle et al., 2012). The major target cells 
for IL-22 in the skin are keratinocytes that express its 
receptor IL-22R. Elevated IL-22 acts on keratinocytes 
in psoriasis skin, inducing many histological features 
of psoriasis, such as acanthosis, hypogranulosis, and 
parakeratosis (Wolk et al., 2009; Wolk et al., 2006; 
Zheng et al., 2007; Wolk et al., 2009). IL-22 may serve 
as a therapeutic target for the treatment of psoriasis.
Recently, it was reported that T cells might be 
the major source of IL-22 in psoriasis. In the present 
study, we observed that IL-22 is mainly produced by 
CD4+ and not by CD8+ T cells in the peripheral blood 
from healthy adults, and that these CD4+ T cells are 
memory cells expressing CD45RO. This result is sim-
ilar with to a previous study (Liu et al., 2011). CD8+ 
T cells could also produce IL-22 in some diseases as 
occurs when CD8+ T cells infiltrate damaged skin in 
psoriasis (Nograles et al., 2009).
It was originally assumed that IL-22 is a Th1-
associated cytokine; later, IL-22 was also linked with 
Th17 cells. Therefore, we compared the percentages 
of these three subsets, and analyzed the correlation of 
IL-22, IL-17 and IFN-γ that were produced by CD4+ 
T cells from healthy adults. Our results show that the 
Fig.  5. CsA inhibits the production of IL-22  by CD4+ T cells  from healthy donors. PBMCs were stimulated with PMA + ionomycin 
in the presence or absence of CsA at different concentrations (0.01 µg/ml, 0.1 µg/ml, 1 µg/ml). After stimulation for 5 h, the cells were 
harvested, fixed, permeabilized, and subjected to cell surface and intracellular cytokine staining for IL-22 and IFN-γ, and assessed by 
FACS. A – the production of IL-22, IFN-γ by CD4+ T cells. Isotype refers to control isotype staining. The numbers in the corner repre-
sent the percentage of positive cells in each quadrant. B – the statistical inhibition ratio of IL-22+ CD4+ T cells and IFN-γ+ CD4+ T cells 
by CsA were calculated and are presented as mean ± S.D. from seven healthy donors in the bar graph; **, P < 0.001; n.s, P> 0.05.782 ERXIA SHEN ET AL.
percentage of Th1 cells in the CD4+ T cell population 
was larger than the percentages of IL-22 producing 
CD4+ T cells and Th17 cells in PBMCs. IL-22+ IFN-γ+ 
and IL-22+ IL-17+ CD4+ T cells exist in PBMCs from 
health donors. CD4+ T cells that produce IL-22 and 
do not produce IL-17 and/or IFN-γ are called Th22 
cells. Similar to previous studies, we demonstrated 
that there is a subset of Th22 cells in adult blood 
(Duhen et al., 2009; Trifari et al., 2009).
Because IL-22 plays a key role in psoriasis pro-
gression, we determined whether CsA inhibits IL-22 
production by CD4+ T cells in healthy donors and 
patients with psoriasis. Our results showed that CsA 
inhibited  IL-22  probuction  by  CD4+  T  cells  from 
healthy donors in a dose-dependent manner. Cir-
culating  Th1,  Th17  and  IL-22  producing  CD4+  T 
cells are increased in psoriasis (Kagami et al., 2010). 
Therefore, we determined whether CsA assumes an 
inhibitory role in psoriasis patients. Our results dem-
onstrated that CsA inhibited IL-22, IFN-γ and IL-17 
production by CD4+ T cells in psoriasis patients. A 
previous study showed that CsA directly inhibits IL-
22 production largely through action on NF-AT in T 
cells (Rudloff et al., 2012), and that CsA could inhibit 
IFN-γ, IL-4 and IL-17 by memory T cells (Tsuda et 
al., 2012).
In conclusion, our study showed that CsA inhib-
its IL-22 production by CD4+ T cells from healthy 
donors and psoriasis patients. Together with previ-
ous studies, our results suggest that CsA could have 
an important therapeutic role in psoriasis by virtue 
of its ability to inhibitIL-22, IFN-γ, and IL-17 release 
by CD4+ T cells.
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